Recent Updates
Recently added Catalysts
ICU Positive Sentiment Score: 75/100

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

Key Takeaway: SeaStar Medical Holding Corporation (Nasdaq: ICU) will present an overview at NobleCon20, held by Noble Capital Markets, on December 4, 2024. The conference aims to highlight emerging growth companies, with SeaStar focusing on its unique solutions for hyperinflammation. A webcast of the presentation will be made available on the company's website, allowing interested parties to access the information after the event. The company's approach emphasizes innovative therapies that could benefit critically ill patients.

Market Sentiment Analysis

POSITIVE FACTORS

  • SeaStar Medical is set to present at a significant conference, indicating growing recognition in the industry.
  • The company's focus on innovative technologies addresses critical health issues related to hyperinflammation.
  • The availability of a webcast for the presentation enables broader access to potential investors and stakeholders.

Full Press Release Details

DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present a company overview at NobleCon20, Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference, on Wednesday, December 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The conference is being held in Boca Raton, Fla.
A webcast of the presentation will be available beginning December 5 on the Company website and will be archived for 90 days.
About SeaStar Medical
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Alliance Advisors IR

Tags

SeaStar Medical Holding Corp
medical device company
Noble Capital Markets’

Frequently Asked Questions

When is SeaStar Medical's presentation at NobleCon20?

SeaStar Medical's presentation will be on December 4 at 12:00 p.m. ET.

Where can I find the webcast of the presentation?

The presentation webcast will be available on the Company website starting December 5.

What does SeaStar Medical focus on?

SeaStar Medical develops solutions to mitigate hyperinflammation effects on vital organs.

How long will the presentation be archived?

The presentation will be archived for 90 days after it is available.

What type of therapies does SeaStar Medical develop?

The company develops cell-directed extracorporeal therapies targeting systemic inflammation.

Last updated: Nov 26, 2024